Antibody or antigen binding fragment thereof for specifically recognizing B cell malignancy, chimeric antigen receptor comprising same and use thereof

A CD19-specific chimeric antigen receptor, comprising the following:

• (a) an extracellular domain comprising an anti-CD19 antibody or an antigen-binding fragment thereof;
• (b) a transmembrane domain;
• and
• (c) an intracellular signaling domain,
• wherein the anti-CD19 antibody or the antigen-binding fragment thereof comprises:
• (i) a heavy chain variable region comprising the following heavy chain complementarity determining region (CDR) amino acid sequences:
• CDRH1 of SEQ ID NO:
• 1, CDRH2 of SEQ ID NO:
• 2, and CDRH3 of SEQ ID NO:
• 3;
• and a light chain variable region comprising the following light chain CDR amino acid sequence:
• CDRL1 of SEQ ID NO:
• 4, CDRL2 of SEQ ID NO:
• 5, and CDRL3 of SEQ ID NO:
• 6;
• (ii) a heavy chain variable region comprising the following heavy chain complementarity determining region (CDR) amino acid sequences:
• CDRH1 of SEQ ID NO:
• 1, CDRH2 of SEQ ID NO:
• 2, and CDRH3 of SEQ ID NO:
• 3;
• and a light chain variable region comprising the following light chain CDR amino acid sequence:
• CDRL1 of SEQ ID NO:
• 4, CDRL2 of SEQ ID NO:
• 5, and CDRL3 of SEQ ID NO:
• 40;
• (iii) a heavy chain variable region comprising the following heavy chain complementarity determining region (CDR) amino acid sequences:
• CDRH1 of SEQ ID NO:
• 1, CDRH2 of SEQ ID NO:
• 2, and CDRH3 of SEQ ID NO:
• 3;
• and a light chain variable region comprising the following light chain CDR amino acid sequence:
• CDRL1 of SEQ ID NO:
• 4, CDRL2 of SEQ ID NO:
• 5, and CDRL3 of SEQ ID NO:
• 41;
• (iv) a heavy chain variable region comprising the following heavy chain complementarity determining region (CDR) amino acid sequences:
• CDRH1 of SEQ ID NO:
• 1, CDRH2 of SEQ ID NO:
• 2, and CDRH3 of SEQ ID NO:
• 30;
• and a light chain variable region comprising the following light chain CDR amino acid sequence:
• CDRL1 of SEQ ID NO:
• 4, CDRL2 of SEQ ID NO:
• 36, and CDRL3 of SEQ ID NO:
• 40;
• (v) a heavy chain variable region comprising the following heavy chain complementarity determining region (CDR) amino acid sequences:
• CDRH1 of SEQ ID NO:
• 1, CDRH2 of SEQ ID NO:
• 2, and CDRH3 of SEQ ID NO:
• 31;
• and a light chain variable region comprising the following light chain CDR amino acid sequence:
• CDRL1 of SEQ ID NO:
• 4, CDRL2 of SEQ ID NO:
• 5, and CDRL3 of SEQ ID NO:
• 40;
• (vi) a heavy chain variable region comprising the following heavy chain complementarity determining region (CDR) amino acid sequences:
• CDRH1 of SEQ ID NO:
• 1, CDRH2 of SEQ ID NO:
• 2, and CDRH3 of SEQ ID NO:
• 32;
• and a light chain variable region comprising the following light chain CDR amino acid sequence:
• CDRL1 of SEQ ID NO:
• 4, CDRL2 of SEQ ID NO:
• 37, and CDRL3 of SEQ ID NO:
• 40;
• (vii) a heavy chain variable region comprising the following heavy chain complementarity determining region (CDR) amino acid sequences:
• CDRH1 of SEQ ID NO:
• 1, CDRH2 of SEQ ID NO:
• 2, and CDRH3 of SEQ ID NO:
• 33;
• and a light chain variable region comprising the following light chain CDR amino acid sequence:
• CDRL1 of SEQ ID NO:
• 4, CDRL2 of SEQ ID NO:
• 38, and CDRL3 of SEQ ID NO:
• 40;
• (viii) a heavy chain variable region comprising the following heavy chain complementarity determining region (CDR) amino acid sequences:
• CDRH1 of SEQ ID NO:
• 1, CDRH2 of SEQ ID NO:
• 2, and CDRH3 of SEQ ID NO:
• 34;
• and a light chain variable region comprising the following light chain CDR amino acid sequence:
• CDRL1 of SEQ ID NO:
• 4, CDRL2 of SEQ ID NO:
• 39, and CDRL3 of SEQ ID NO:
• 40;
• or
• (ix) a heavy chain variable region comprising the following heavy chain complementarity determining region (CDR) amino acid sequences:
• CDRH1 of SEQ ID NO:
• 1, CDRH2 of SEQ ID NO:
• 2, and CDRH3 of SEQ ID NO:
• 35;
• and a light chain variable region comprising the following light chain CDR amino acid sequence:
• CDRL1 of SEQ ID NO:
• 4, CDRL2 of SEQ ID NO:
• 5, and CDRL3 of SEQ ID NO:
• 40.